On October 29, 2020 PellePharm, Inc., a BridgeBio Pharma, Inc. company, reported the presentation of various data highlighting product candidate patidegib topical gel for adults with Gorlin syndrome and high-frequency basal cell carcinoma (HF-BCC) (Press release, PellePharm, OCT 29, 2020, View Source [SID1234569388]). The presentations will be made during the 29th Congress of the European Academy of Dermatology and Venereology (EADV), to be held virtually October 29 – 31, 2020.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Patidegib topical gel is in development to reduce the large volume of basal cell carcinoma (BCC) tumors that characterize Gorlin syndrome and HF-BCC, at their source, by inhibiting the hedgehog signaling pathway. It is designed to block the SMO signal, thus turning off oncogenic hedgehog activity. Unlike other hedgehog inhibitors, patidegib has been formulated into a topical gel that is stable at room temperature for use as a chronic therapy.
"For rare diseases such as Gorlin syndrome and HF-BCC, with symptoms that manifest on the skin and require treatments that are either invasive or poorly tolerated, we believe that a topical therapeutic designed to both reduce BCC burden and minimize systemic exposure and thereby side effects is ideal for this vulnerable patient population," said Sanuj K. Ravindran, M.D., president and chief executive officer of PellePharm. "Our research continues to generate compelling evidence that supports patidegib as a clinical candidate and validates our approach in hedgehog inhibition."
Details for the poster presentations at EADV Virtual are as follows:
Poster Title: A Phase 1, Single-center, Pharmacokinetic, Safety and Tolerability Study of Patidegib Topical Gel in Healthy Adult Volunteers Under Maximum Use Conditions
Date & Time: Thursday, October 29, 2020, 12:00 p.m. CET
Category: Cutaneous Oncology
Poster Title: A Proof of Concept, Phase 2 Study to Assess Efficacy and Safety of Patidegib for Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Non-Gorlin High-Frequency BCC Patients
Date & Time: Thursday, October 29, 2020, 12:00 p.m. CET
Category: Cutaneous Oncology
Poster Title: A Phase 3 Pivotal Study to Assess Efficacy and Safety of Patidegib for Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Gorlin Syndrome
Date & Time: Thursday, October 29, 2020, 12:00 p.m. CET
Category: Cutaneous Oncology
Poster Title: Gorlin Syndrome: It’s the Pits*
Date & Time: Thursday, October 29, 2020, 12:00 p.m. CET
Category: Cutaneous Oncology
*This poster is presented by Julie Breneiser on behalf of GSA (Gorlin Syndrome Alliance).
"We are encouraged by the continuing promise that patidegib is demonstrating in the clinic. A topical formulation has the potential to bring significant benefit to the Gorlin Syndrome patient and for patients with HF-BCC, helping manage the burden of the diseases with convenient self-administration at home," said Patrice Baudry, vice president of rare disease at LEO Pharma.
In November 2018, PellePharm and LEO Pharma entered into a strategic collaboration to address the unmet medical needs for rare skin conditions, such as Gorlin syndrome and HF-BCC. LEO Pharma is providing resources to PellePharm to fund, among other activities, its Phase 3 trial of patidegib topical gel 2% in patients with Gorlin syndrome under the terms of the agreement.
About Patidegib
Patidegib topical gel, an investigational treatment, is designed to reduce the basal cell carcinoma (BCC) tumor burden in people living with Gorlin syndrome and high frequency BCC (HF-BCC) by blocking the disease at its source within the hedgehog signaling pathway. Patidegib topical gel has shown early promise in a Phase 2 clinical study for the mitigation of BCC tumors in Gorlin syndrome. The topical formulation of patidegib was developed with a goal of providing the clinical activity previously demonstrated by oral Patidegib in Phase 1 trials and a favorable tolerability profile without the adverse systemic side effects observed with the oral class of hedgehog inhibitors. The topical gel formulation is stable at room temperature for at least two years, potentially making it an option for ongoing, at-home management of Gorlin syndrome and HF-BCC. PellePharm has received both Orphan Drug Designation and Breakthrough Therapy Designation for Patidegib Topical Gel in Gorlin Syndrome from the FDA, as well as Orphan Drug Designation in Gorlin Syndrome from EMA’s Committee for Orphan Medicinal Products in the EU.
About Gorlin Syndrome
Gorlin syndrome is a rare, genetic disease characterized by constitutional, heritable mutations in one allele of the tumor suppressor gene encoding PATCHED1 (PTCH1), which acts as the primary inhibitor of the hedgehog signaling pathway. This leads to the formation of multiple basal cell carcinomas (BCCs), often on the face.
With no FDA-approved drugs available for people living with Gorlin syndrome, the standard of care for treating BCCs is surgery. People with severe Gorlin syndrome may have as many as 30 surgeries per year, which can be repetitive, scarring and disfiguring. Approximately 10,000 people in the United States, or one in 31,000, are believed to be affected by Gorlin syndrome. Gorlin syndrome is known by several names, including Gorlin-Goltz syndrome, basal cell nevus syndrome (BCNS) and Nevoid Basal Cell Carcinoma Syndrome (NBCCS).
About High Frequency Basal Cell Carcinoma (HF-BCC)
HF-BCC, like Gorlin syndrome, is a rare disease which is characterized by the development of an abnormally high number of basal cell carcinomas (BCCs). Unlike people with Gorlin syndrome, people with HF-BCC are not born with a germline PTCH1 mutation and do not suffer from the other systemic manifestations of Gorlin syndrome. The current standard of care for people living with HF-BCC is BCC surgery.